Because LB100, a PP2A inhibitor, has the ability to convert cold MSS tumours into hot MSI tumours, thereby inhibiting Treg infiltration by the tumour itself, there is no need to combine Treg inhibition for enhancing ICB response. The gene discussed is PTPA; the disease is neoplasm.